文献速递湿疹皮炎与荨麻疹

真实世界难治性特应性皮炎患者乌帕替尼治疗队列

Upadacitinib treatment in a real-world difficult-to-treat atopic dermatitis patient cohort.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-11-16

中位随访37.5周,IGA中位数从基线3降至末次评估1.5(p<0.001),瘙痒NRS从7降至2.25(p<0.001)。71%患者仍在用药,29%因无效或不良事件停药。

要点

  • 81%患者曾对其他靶向治疗(含JAK抑制剂和生物制剂)无效。
  • IGA中位数从3降至1.5,瘙痒NRS从7降至2.25,均p<0.001。

核心结论

  • 在真实世界难治性AD队列中,乌帕替尼对部分既往多种系统免疫抑制和生物制剂治疗失败的患者有效。
  • 不良事件总体耐受性良好,多数患者未因不良事件停药。

主要发现

  • 中位随访37.5周,IGA中位数从基线3(IQR 2-3)降至末次评估1.5(IQR 1-2),p<0.001。
  • 瘙痒NRS中位数从基线7(IQR 5-8)降至末次评估2.25(IQR 0.25-6.5),p<0.001。

临床怎么用

  • 在既往多种系统免疫抑制和生物制剂治疗失败的中重度AD患者中,乌帕替尼治疗可显著降低疾病严重度和瘙痒。
  • 治疗过程中需关注痤疮样皮疹、恶心和呼吸道感染等不良事件。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Upadacitinib was the first JAK-1 selective inhibitor registered for the treatment of moderate-to-severe atopic dermatitis (AD). Although efficacy and safety have been shown in clinical trials, real-world data on the use of upadacitinib in patients that have been treated with other immunosuppressants and targeted therapies is limited. OBJECTIVES: To provide real-world evidence on the use of upadacitinib treatment in moderate-to-severe atopic dermatitis. METHODS: In this prospective observational single-centre study, all AD patients treated with upadacitinib treatment in the context of standard care were included between August 2021 and September 2022. Clinical outcome measures and adverse events (AEs) were analysed. RESULTS: Forty-eight patients were included. The majority (n = 39; 81%) had failed (ineffectiveness) on other targeted therapies, including other JAK inhibitors and biologics. Thirty-four (71%) patients were still using upadacitinib treatment at last follow up (median duration 46.5 weeks). Fourteen (29%) patients discontinued treatment due to ineffectiveness or AE. Upadacitinib treatment led to a significant decrease of disease severity during a median follow up of 37.5 weeks. Median IGA at baseline decreased from 3 (IQR 2-3) to 1.5 (IQR 1-2) at last review (p < 0.001). Median NRS itch decreased from 7 (IQR 5-8) at baseline to 2.25 (IQR 0.25-6.5) at last review (p < 0.001). Three patients discontinued treatment due to AE. Forty-eight AEs were reported, including acne-like eruptions (25%), nausea (13%) and respiratory tract infections (10%). CONCLUSIONS: In this real-world cohort, we confirmed that upadacitinib is an effective treatment in a subset of AD patients that have failed several previous systemic immunosuppressive and biologic treatments. Overall, AE were mostly well tolerated and not a reason to discontinue treatment for most patients.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Schlösser AR, Boeijink N, Olydam J, et al. Upadacitinib treatment in a real-world difficult-to-treat atopic dermatitis patient cohort. J Eur Acad Dermatol Venereol. 2023. PMID: 37864486. doi:10.1111/jdv.19581

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。